Pheochromocytoma Therapeutic Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com

Share Article

RnRMarketResearch.com adds “Pheochromocytoma – Pipeline Review, H1 2015” to its store. The report provides an overview of the Pheochromocytoma’s therapeutic pipeline.

Pheochromocytoma Therapeutic Pipeline

Pheochromocytoma Therapeutic Pipeline

The report “Pheochromocytoma – Pipeline Review, H1 2015” provides comparative analysis on the therapeutic development for Pheochromocytoma. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on H1 2015 pipeline review of Pheochromocytoma with 19 market data tables and 13 figures, spread across 64 pages is available at http://www.rnrmarketresearch.com/pheochromocytoma-pipeline-review-h1-2015-market-report.html .

Companies discussed in this Pheochromocytoma – Pipeline Review, H1 2015 report include AstraZeneca PLC, Exelixis, Inc., MediaPharma s.r.l., Pfizer Inc., Progenics Pharmaceuticals, Inc.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are cabozantinib s-malate, iobenguane sulfate I 131, MPHE-001B, S-43126, sunitinib malate, vandetanib. Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=382516 . (This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases cover by this report includes: Mar 02, 2015: Progenics Pharmaceuticals Announces Presentation at ENDO 2015; Jan 23, 2015: Progenics Pharmaceuticals Relaunches Pivotal Trial of AZEDRA in Pheochromocytoma; Sep 22, 2014: Progenics Pharmaceuticals Presents Long Term Follow-Up of Pivotal Phase 2 Trial of Azedra in Malignant Pheochromocytoma; Apr 01, 2014: Progenics Pharmaceuticals and Centre for Probe Development and Commercialization Announce Agreement to Manufacture Targeted Radiotherapeutic Candidate for Ultra-Orphan Indications; Nov 25, 2013: Progenics Pharmaceuticals Relaunching Registrational Trial of Azedra to Treat Pheochromocytomas.
List of Tables
Number of Products under Development for Pheochromocytoma, H1 2015 7
Number of Products under Development for Pheochromocytoma - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Products under Investigation by Universities/Institutes, H1 2015 14
Pheochromocytoma - Pipeline by AstraZeneca PLC, H1 2015 15
Pheochromocytoma - Pipeline by Exelixis, Inc., H1 2015 16
Pheochromocytoma - Pipeline by MediaPharma s.r.l., H1 2015 17
Pheochromocytoma - Pipeline by Pfizer Inc., H1 2015 18
Pheochromocytoma - Pipeline by Progenics Pharmaceuticals, Inc., H1 2015 19
Assessment by Monotherapy Products, H1 2015 20
Number of Products by Stage and Target, H1 2015 22
Number of Products by Stage and Mechanism of Action, H1 2015 24
Number of Products by Stage and Route of Administration, H1 2015 26
Number of Products by Stage and Molecule Type, H1 2015 27
Pheochromocytoma Therapeutics - Recent Pipeline Updates, H1 2015 45
List of Figures
Number of Products under Development for Pheochromocytoma, H1 2015 7
Number of Products under Development for Pheochromocytoma - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Products, H1 2015 12
Assessment by Monotherapy Products, H1 2015 20
Number of Products by Top 10 Targets, H1 2015 21
Number of Products by Stage and Top 10 Targets, H1 2015 21
Number of Products by Top 10 Mechanism of Actions, H1 2015 23
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 24
Number of Products by Top 10 Routes of Administration, H1 2015 25
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 26
Number of Products by Stage and Top 10 Molecule Types, H1 2015 27

Explore more reports on Allergy therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/allergy-therapeutics .

About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
@RnRMR
since: 06/2012
Follow >
RnR Market Research
Like >
Follow us on
Visit website